AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34670600 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing (time and attention control task)
Number of subjects: 0
Study 34670760 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital phenotyping using smartphone and wrist-wearable device
Number of subjects: 100
Study 34670760 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital phenotyping
Number of subjects: 100
Study 34670762 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcome for Fighting Financial Toxicity (PROFFIT) instrument consisting of 16 items measuring financial toxicity (FT) of cancer.
Number of subjects: 184
Study 34670762 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-item prefinal questionnaire administered electronically or by paper sheet.
Number of subjects: 184
Study 34671036 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 34671067 — intervention group
Group type: EXPERIMENTAL
Intervention: High TG and low HDL-C levels (expressed by TG/HDL-C ratio)
Number of subjects: 355
Study 34671067 — intervention group
Group type: EXPERIMENTAL
Intervention: Global CTA risk score
Number of subjects: 355
Study 34671131 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinflunine 320 mg/m², 4 cycles
Number of subjects: 25
Study 34671652 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34671764 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Group Therapy
Number of subjects: 0
Study 34671975 — intervention group
Group type: EXPERIMENTAL
Intervention: melflufen plus dexamethasone
Number of subjects: 64
Study 34672131 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 227
Study 34672224 — intervention group
Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 2196
Study 34672224 — intervention group
Group type: COMPARATOR
Intervention: PCV20
Number of subjects: 2196
Study 34672246 — intervention group
Group type: EXPERIMENTAL
Intervention: CD79-targeted chimeric antigen receptor (CAR) T-cell therapy
Number of subjects: 59
Study 34672246 — intervention group
Group type: EXPERIMENTAL
Intervention: MFC panel with cCD79a gating
Number of subjects: 59
Study 34672659 — intervention group
Group type: EXPERIMENTAL
Intervention: Interview-based networks
Number of subjects: 0
Study 34672659 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report networks
Number of subjects: 0
Study 34672794 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34672961 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib plus azacitidine
Number of subjects: 107
Study 34672961 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine only
Number of subjects: 107
Study 34672967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 5 mg
Number of subjects: 2002
Study 34672967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 10 mg
Number of subjects: 2002
Study 34672967 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide 15 mg
Number of subjects: 2002
Study 34672967 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 2002
Study 34673442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 400 mg/day
Number of subjects: 570
Study 34673442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib 300 mg/day
Number of subjects: 570
Study 34673442 — intervention group
Group type: COMPARATOR
Intervention: Bosutinib 500 mg/day (matched controls)
Number of subjects: 570
Study 34673442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosutinib (dose reduction)
Number of subjects: 570
Study 34673502 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 640
Study 34673897 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 349
Study 34673897 — intervention group
Group type: EXPERIMENTAL
Intervention: IMWG-GA criteria
Number of subjects: 349
Study 34673897 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 349
Study 34673897 — intervention group
Group type: EXPERIMENTAL
Intervention: MNA-SF score (MNA-SF ≥ 12), GDS score (GDS ≤ 5), CCI score (CCI ≥ 2)
Number of subjects: 349
Study 34674223 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninterrupted anticoagulation therapy
Number of subjects: 4714
Study 34674223 — intervention group
Group type: COMPARATOR
Intervention: Interrupted anticoagulation therapy (minimal interruption strategy)
Number of subjects: 4714
Study 34674223 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete interruption of VKA
Number of subjects: 4714
Study 34674223 — intervention group
Group type: COMPARATOR
Intervention: Composite endpoint of thromboembolic events (stroke, systemic embolism, major bleeding, and all-cause mortality)
Number of subjects: 4714
Study 34674223 — intervention group
Group type: COMPARATOR
Intervention: Major and minor bleeding
Number of subjects: 4714
Study 34674223 — intervention group
Group type: COMPARATOR
Intervention: All-cause mortality
Number of subjects: 4714
Study 34674223 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic thromboembolic events
Number of subjects: 4714
Study 34674270 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR-A score
Number of subjects: 86
Study 34674490 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg nightly for 8 weeks
Number of subjects: 40
Study 34674490 — intervention group
Group type: COMPARATOR
Intervention: Placebo nightly for 8 weeks
Number of subjects: 40
Study 34674592 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH) using a commercially available infrared sauna device (Curve Sauna Dome) for a single session lasting up to 110 minutes
Number of subjects: 25
Study 34674592 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia (WBH)
Number of subjects: 25
Study 34674669 — intervention group
Group type: EXPERIMENTAL
Intervention: RNT-targeting app for 6 weeks
Number of subjects: 204
Study 34674669 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control (no app for 6 weeks)
Number of subjects: 204
Study 34674705 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants of cholinergic genes CHRM2 and CHRM4
Number of subjects: 745
Study 34674732 — intervention group
Group type: EXPERIMENTAL
Intervention: ASSIP + SPP
Number of subjects: 411
Study 34674732 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + SPP
Number of subjects: 411
Study 34674732 — intervention group
Group type: COMPARATOR
Intervention: SPP
Number of subjects: 411
Study 34674733 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 6542
Study 34674733 — intervention group
Group type: EXPERIMENTAL
Intervention: High fever
Number of subjects: 6542
Study 34674733 — intervention group
Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 6542
Study 34674739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (65 Gy in 2.5-Gy fractions)
Number of subjects: 0
Study 34674739 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy (66 Gy in 2-Gy fractions)
Number of subjects: 0
Study 34674739 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 0
Study 34674739 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy
Number of subjects: 0
Study 34674737 — intervention group
Group type: COMPARATOR
Intervention: Supervised RSA biofeedback intervention in adolescents with ASD (n=128)
Number of subjects: 230
Study 34674737 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-supervised RSA biofeedback intervention in adolescents with ASD (n=64)
Number of subjects: 230
Study 34674737 — intervention group
Group type: COMPARATOR
Intervention: Adolescents with ASD (n=38)
Number of subjects: 230
Study 34674738 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTIFS training intervention for 12 weeks
Number of subjects: 106
Study 34674738 — intervention group
Group type: COMPARATOR
Intervention: Care-as-Usual (current neuromuscular training)
Number of subjects: 106
Study 34674738 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTIFS training intervention
Number of subjects: 106
Study 34674738 — intervention group
Group type: COMPARATOR
Intervention: Care-as-Usual
Number of subjects: 106
Study 34674742 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA vaccine Comirnaty® (Pfizer/BioNTech)
Number of subjects: 380
Study 34674742 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 mRNA Vaccine Moderna®
Number of subjects: 380
Study 34674803 — intervention group
Group type: EXPERIMENTAL
Intervention: Light physical activity (LPA) in APOE-ɛ4 carriers
Number of subjects: 190
Study 34674803 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA) in APOE-ɛ4 carriers
Number of subjects: 190
Study 34674803 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-carriers of APOE-ɛ4)
Number of subjects: 190
Study 34674821 — intervention group
Group type: EXPERIMENTAL
Intervention: Early impedance-guided intervention
Number of subjects: 0
Study 34675018 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game therapy (VGT) on commercial video game console, 1 hour training session over 4 weeks (three sessions/week)
Number of subjects: 48
Study 34675018 — intervention group
Group type: COMPARATOR
Intervention: Standardised balance platform training (BPT), 1 hour training session over 4 weeks (three sessions/week)
Number of subjects: 48
Study 34675018 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game therapy (VGT)
Number of subjects: 48
Study 34675018 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game therapy (VGT) and Standardised balance platform training (BPT)
Number of subjects: 48
Study 34675020 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric venous outflow reconstruction during TP
Number of subjects: 20
Study 34675020 — intervention group
Group type: COMPARATOR
Intervention: Standard post-TP care and treatment
Number of subjects: 20
Study 34675043 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival
Number of subjects: 206
Study 34675043 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic respiratory failure (CRF) and pulmonary hypertension (PH)
Number of subjects: 206
Study 34675043 — intervention group
Group type: EXPERIMENTAL
Intervention: Malignant diseases
Number of subjects: 206
Study 34675043 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapulmonary involvement
Number of subjects: 206
Study 34675050 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression index model based on tertiles of circulating concentrations of biomarkers (osteopontin, matrix metallopeptidase-7, intercellular adhesion molecule-1, periostin)
Number of subjects: 516
Study 34675050 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical model incorporating the progression index
Number of subjects: 516
Study 34675068 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation suggestive of pancreatic duct obstruction
Number of subjects: 201
Study 34675068 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal pain processing
Number of subjects: 201
Study 34675068 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 201
Study 34675068 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 201
Study 34675068 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain catastrophising
Number of subjects: 201
Study 34675068 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of two or more factors
Number of subjects: 201
Study 34675068 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distress
Number of subjects: 201
Study 34675105 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary biomarkers IGF-1 and IGFBP5 multiplexed with single-task gait velocity
Number of subjects: 95
Study 34675105 — intervention group
Group type: COMPARATOR
Intervention: Healthy control collegiate athletes
Number of subjects: 95
Study 34675114 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 exon 4-intron 4 splice junction variants
Number of subjects: 0
Study 34675114 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34675131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment
Number of subjects: 291292
Study 34675131 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive treatment
Number of subjects: 291292
Study 34675131 — intervention group
Group type: COMPARATOR
Intervention: Pharmacologic treatment only
Number of subjects: 291292
Study 34675131 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment trends
Number of subjects: 291292
Study 34675151 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate-haptic toric IOL (AT TORBI 709M IOL) implantation
Number of subjects: 102
Study 34675344 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D polymorphisms (specifically in the GC gene)
Number of subjects: 517
Study 34675344 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D polygenic risk score
Number of subjects: 517
Study 34675344 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum concentration of 25 (OH)D
Number of subjects: 517
Study 34675344 — intervention group
Group type: COMPARATOR
Intervention: DHCR7 RS12785878 variant prevalence
Number of subjects: 517
Study 34675476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (RBZ) treatment, pro re nata regimen, mean number of injections 5.18 (range 2-6)
Number of subjects: 31
Study 34675476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (RBZ) treatment in non-vitrectomized eyes (group 2)
Number of subjects: 31
Study 34675644 — intervention group
Group type: EXPERIMENTAL
Intervention: Fu's subcutaneous needling (FSN) treatment
Number of subjects: 0
Study 34675644 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation treatment
Number of subjects: 0
Study 34675644 — intervention group
Group type: EXPERIMENTAL
Intervention: FSN treatment
Number of subjects: 0
Study 34675881 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 37
Study 34675881 — intervention group
Group type: COMPARATOR
Intervention: Dietary advice
Number of subjects: 37
Study 34676191 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily disinfection of the endoscopy unit
Number of subjects: 0
Study 34676191 — intervention group
Group type: COMPARATOR
Intervention: After-each-case disinfection of the endoscopy unit
Number of subjects: 0
Study 34676467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisexual men
Number of subjects: 290
Study 34676467 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisexual men (adjusted for race, education, and income)
Number of subjects: 290
Study 34677135 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart belt ECG monitoring system
Number of subjects: 159
Study 34677138 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Wharton jelly-derived mesenchymal stem cells (WJ-MSCs) alone
Number of subjects: 10
Study 34677138 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal stem cells (NSCs) and Wharton jelly-derived mesenchymal stem cells (WJ-MSCs)
Number of subjects: 10
Study 34677138 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving allogeneic WJ-MSCs alone
Number of subjects: 10
Study 34677248 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with a partner
Number of subjects: 3004
Study 34677248 — intervention group
Group type: EXPERIMENTAL
Intervention: Being married (among women living with a partner)
Number of subjects: 3004
Study 34677248 — intervention group
Group type: EXPERIMENTAL
Intervention: Having three or more children (vs. none) among women with low household income
Number of subjects: 3004
Study 34677608 — intervention group
Group type: EXPERIMENTAL
Intervention: Metreleptin therapy
Number of subjects: 67
Study 34677608 — intervention group
Group type: COMPARATOR
Intervention: RIA leptin assay
Number of subjects: 67
Study 34677608 — intervention group
Group type: COMPARATOR
Intervention: MELISA leptin assay
Number of subjects: 67
Study 34677608 — intervention group
Group type: COMPARATOR
Intervention: RDELISA leptin assay
Number of subjects: 67
Study 34678156 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening in MSH2 carriers
Number of subjects: 828
Study 34678156 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening in MSH6 carriers
Number of subjects: 828
Study 34678156 — intervention group
Group type: COMPARATOR
Intervention: PSA screening in MSH2 non-carrier controls
Number of subjects: 828
Study 34678156 — intervention group
Group type: COMPARATOR
Intervention: PSA screening in MSH6 non-carrier controls
Number of subjects: 828
Study 34678156 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall positive predictive value of biopsy using PSA threshold of 3.0 ng/mL
Number of subjects: 828
Study 34678156 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall positive predictive value of PSA threshold of 3.0 ng/mL
Number of subjects: 828
Study 34678329 — intervention group
Group type: EXPERIMENTAL
Intervention: Expect With Me (EWM) group prenatal care
Number of subjects: 2402
Study 34678329 — intervention group
Group type: EXPERIMENTAL
Intervention: Expect With Me (EWM) group prenatal care (using integrated information technology platform)
Number of subjects: 2402
Study 34678329 — intervention group
Group type: COMPARATOR
Intervention: Individual care only
Number of subjects: 2402
Study 34678678 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab alone (4 mg/kg initial dose then 2 mg/kg weekly for 5 weeks)
Number of subjects: 82
Study 34678678 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab combined with everolimus (10 mg/day for 6 weeks)
Number of subjects: 82
Study 34678750 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspapers
Number of subjects: 4921
Study 34678750 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media
Number of subjects: 4921
Study 34678750 — intervention group
Group type: EXPERIMENTAL
Intervention: Online interactive media
Number of subjects: 4921
Study 34678750 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional media
Number of subjects: 4921
Study 34678750 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance of COVID-19-related information
Number of subjects: 4921
Study 34678845 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler-based resistive index
Number of subjects: 371
Study 34678845 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative evaluation of renal perfusion
Number of subjects: 371
Study 34678845 — intervention group
Group type: COMPARATOR
Intervention: Doppler-based measurements by expert operators
Number of subjects: 371
Study 34678845 — intervention group
Group type: COMPARATOR
Intervention: Doppler-based measurements by nonexpert operators
Number of subjects: 371
Study 34678845 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for resistive index
Number of subjects: 371
Study 34678845 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for semiquantitative evaluation of renal perfusion
Number of subjects: 371
Study 34678870 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (atibuclimab) 2 mg/kg IV followed by 1 mg/kg/d IV × 3 (n=3)
Number of subjects: 10
Study 34678870 — intervention group
Group type: EXPERIMENTAL
Intervention: IC14 (atibuclimab) 4 mg/kg IV followed by 2 mg/kg/d IV × 3 (n=7)
Number of subjects: 10
Study 34681128 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical masks
Number of subjects: 63
Study 34681128 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP3 filtering respirators
Number of subjects: 63
Study 34682453 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR group)
Number of subjects: 62
Study 34682453 — intervention group
Group type: COMPARATOR
Intervention: Specific Therapeutic Exercises (STE group)
Number of subjects: 62
Study 34682794 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization for myocarditis
Number of subjects: 19978
Study 34682794 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure/cardiomyopathy hospitalization
Number of subjects: 19978
Study 34682794 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation hospitalization
Number of subjects: 19978
Study 34682794 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-year survival rates
Number of subjects: 19978
Study 34682794 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence trends
Number of subjects: 19978
Study 34682794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic tests performance
Number of subjects: 19978
Study 34682794 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates comparison
Number of subjects: 19978
Study 34683180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing including 50 single nucleotide polymorphisms (SNPs) from 39 genes
Number of subjects: 416
Study 34683180 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfactory response to BS defined as nadir excess weight loss >50%
Number of subjects: 416
Study 34684360 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT2 program (smoking cessation therapy with individualized coaching in diet and physical activity strategies for PCWG restriction)
Number of subjects: 590
Study 34684360 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 590
Study 34684372 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (pHF) containing low lactose and probiotics
Number of subjects: 80
Study 34684546 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake intervention (not specified in detail)
Number of subjects: 0
Study 34684546 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity evaluation (not specified in detail)
Number of subjects: 0
Study 34684546 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (not specified in detail)
Number of subjects: 0
Study 34685448 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 308
Study 34685481 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychomotor Vigilance Test (PVT) during total sleep deprivation
Number of subjects: 47
Study 34685481 — intervention group
Group type: EXPERIMENTAL
Intervention: Go/noGo executive inhibition task during total sleep deprivation
Number of subjects: 47
Study 34685481 — intervention group
Group type: EXPERIMENTAL
Intervention: Karolinska Sleepiness Scale (KSS) during total sleep deprivation
Number of subjects: 47